Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
10/10/24 | Stealth Biotherapeutics | Elamipretide (Systemic Delivery) for Cardiomyopathy - Dilated | Subscribers Only | Subscribers Only | Subscribers Only |
10/9/24 | Clearside (CLSD) | CLS-AX for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
10/8/24 | Stealth Biotherapeutics | Elamipretide (Systemic Delivery) for Cardiomyopathy - Dilated | Subscribers Only | Subscribers Only | Subscribers Only |
10/8/24 | Merck (MRK) | Keytruda for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
9/27/24 | Johnson (JNJ) | Darzalex Faspro for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
09/30/2024 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
10/12/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
10/12/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
10/13/2024 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |